Current and future of immunotherapy for thyroid cancer based on bibliometrics and clinical trials

Background Thyroid cancer is a leading endocrine malignancy, with anaplastic and medullary subtypes posing treatment challenges. Existing therapies have limited efficacy, highlighting a need for innovative approaches. Methods We analyzed 658 articles and 87 eligible clinical trials using bibliometri...

Full description

Saved in:
Bibliographic Details
Published in:Discover. Oncology 2024-02, Vol.15 (1), p.50-50, Article 50
Main Authors: Wang, Ke, Zhang, Ying, Xing, Yang, Wang, Hong, He, Minghua, Guo, Rui
Format: Article
Language:English
Subjects:
Antibodies
Bibliometrics
Cancer Research
Cancer therapies
Citations
Clinical Trials
Cytokines
Growth factors
Immune checkpoint inhibitor
Immunization
Immunotherapy
Internal Medicine
Iodine
Medicine
Medicine & Public Health
Molecular Medicine
Oncology
PD-1/PD-L1
Radiotherapy
Regulatory approval
Review
Scientometric analysis
Scientometrics
Surgical Oncology
Thyroid cancer
Tumors
Vaccines
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Thyroid cancer is a leading endocrine malignancy, with anaplastic and medullary subtypes posing treatment challenges. Existing therapies have limited efficacy, highlighting a need for innovative approaches. Methods We analyzed 658 articles and 87 eligible clinical trials using bibliometric tools and database searches, including annual publication and citation trends, were executed using Web of Science, CiteSpace, and VOS Viewer. Results Post-2018, there is a surge in thyroid cancer immunotherapy research, primarily from China and the University of Pisa. Of the 87 trials, 32 were Phase I and 55 were Phase II, mostly exploring combination therapies involving immune checkpoint inhibitors. Conclusion The study's dual approach verifies the swift advancement of thyroid cancer immunotherapy from diverse perspectives. Immune checkpoint inhibitors have become the preferred regimen for advanced MTC and ATC in late therapeutic lines. However, since ICB plays a pivotal role in ATC, current clinical trial data show that ATC patients account for more and the curative effect is more accurate. Anticipated future developments are inclined toward combination regimens integrating immunotherapy with chemotherapy or targeted therapies. Emerging approaches, such as bispecific antibodies, cytokine-based therapies, and adoptive cell therapies like CAR-T and TCR-T, are exhibiting considerable potential. Upcoming research is expected to concentrate on refining the tumor immune milieu and discovering novel biomarkers germane to immunotherapeutic interventions.
ISSN:2730-6011
2730-6011
DOI:10.1007/s12672-024-00904-6